Insulet (NSDQ:PODD) posted second-quarter results this week that beat the revenue consensus on Wall Street but missed on earnings estimates. The Acton, Mass.-based company reported losses of -$25 million, or -37¢ per share, on sales of $263.2 million for the three months ended June 30 for a sales growth of 16.31% compared with Q2 2020. Earnings […]
Insulet
Insulet shares down after Q1 miss
Insulet (NSDQ:PODD) stock is down today — a day after the wearable insulin delivery system developer posted break-even Q1 results that were lower than analysts’ expectations. The company, however, yesterday evening raised the low end of its revenue guidance range to 16–20%. The range was previously 15–20%. The Acton, Mass.-based company a net loss of […]
Insulet touts results from Omnipod 5 study, expects launch this year
Insulet (NSDQ:PODD) touted positive results from the first pivotal trial for its Omnipod 5 automated insulin delivery system. Omnipod 5 is the world’s first tubeless, wearable system designed to continuously adapt insulin delivery based on glucose levels and trends, according to a news release. Acton, Mass.-based Insulet said the device, which has FDA breakthrough device […]
DTW Podcast: Insulet CEO Petrovic sees abundance of CGM opportunities
Medtech startups developing continuous glucose monitors have caught the eye of at least one potential – and powerful – partner – Insulet. In an interview with the DeviceTalks Weekly Podcast, CEO Shacey Petrovic said the maker of the OmniPod insulin-delivery device sees partnering with other companies as the likely path to creating a single device […]
Insulet rises on Street-beating Q4 revenues
Insulet (NSDQ:PODD) shares rose before the market opened today on fourth-quarter results that beat the consensus revenue forecast. The Acton, Mass.-based wearable insulin delivery system developer posted losses of -$17.1 million, or -26¢ per share, on sales of $246.1 million for the three months ended Dec. 31, 2020, for a bottom-line slide into the red on […]
Global wearable patch market growing at 10.6% rate
Researchers say that the global wearable patch market size is expected to reach $12.6 billion by 2026, marking a massive rise over five years. According to the research, put together by ResearchAndMarkets.com, the rise is expected to represent a compound annual growth rate of 10.6% during the forecast period. Wearables covered by the research, including […]
Insulet surpasses Q3 earnings estimates, raises guidance
Insulet (NSDQ:PODD) posted third-quarter results after market close yesterday that beat analysts’ consensus for the company. The Acton, Mass.-based tubeless insulin pump manufacturer announced profits of $11.6 million or $0.17 per share on sales of $234 million for the three months ended September 30, 2020, for a bottom-line gain of 13.5% on sales growth of 21% compared […]
Insulet up on Street-beating Q2, raised guidance
Insulet (NSDQ:PODD) shares ticked up today on second-quarter results that topped the consensus forecast. The Acton, Mass.-based wearable insulin delivery system developer posted profits of $14.4 million, or 22¢ per share, on sales of $226.3 million for the three months ended June 30, 2020, for a bottom-line gain of nearly ten times as much as last […]
Insulet installs thousands of solar panels at global HQ
Insulet (NSDQ:PODD) announced today that its corporate headquarters and manufacturing facility will be powered by solar-based, renewable energy. The Acton, Mass.-based facility is set to turn to the new energy source, beginning this week. The company covered its 58,000 square-foot manufacturing facility with approximately 2,800 solar panels to, during optimal climate conditions, generate enough energy to […]
Insulet resumes next-gen Omnipod pivotal study following software issues
Insulet (NSDQ:PODD) today said it has resumed its pivotal study of its next-generation Omnipod Insulin Management System after pausing the study in March due to a software anomaly. The company paused the study about halfway through completion to correct an issue that could result in the system using an incorrect glucose value that had the potential to impact […]
